Drugs / warfarrin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07132515 | Aug 2023 → Aug 2025 overdue | cirrhosis of liver, hepatocellular carcinoma, portal vein thrombosis | Mansoura University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | warfarrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07132515 ↗ |
| Known as | marivan | “HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)” NCT07132515 ↗ |